BRPI1012993A2 - "uso de um anticorpo anti-tau ps422 para o tratamento de doenças do cérebro" - Google Patents

"uso de um anticorpo anti-tau ps422 para o tratamento de doenças do cérebro"

Info

Publication number
BRPI1012993A2
BRPI1012993A2 BRPI1012993A BRPI1012993A BRPI1012993A2 BR PI1012993 A2 BRPI1012993 A2 BR PI1012993A2 BR PI1012993 A BRPI1012993 A BR PI1012993A BR PI1012993 A BRPI1012993 A BR PI1012993A BR PI1012993 A2 BRPI1012993 A2 BR PI1012993A2
Authority
BR
Brazil
Prior art keywords
tau
antibody
treatment
brain disease
brain
Prior art date
Application number
BRPI1012993A
Other languages
English (en)
Inventor
Bohrmann Bernd
Grueninger Fiona
Krell Hans-Willi
Ozmen Laurence
Schraeml Michael
Mundigl Olaf
Offner Sonja
Goepfert Ulrich
Lifke Valeria
Huber Walter
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI1012993A2 publication Critical patent/BRPI1012993A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
BRPI1012993A 2009-06-10 2010-06-08 "uso de um anticorpo anti-tau ps422 para o tratamento de doenças do cérebro" BRPI1012993A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09007656 2009-06-10
EP09008487 2009-06-30
PCT/EP2010/003437 WO2010142423A2 (en) 2009-06-10 2010-06-08 Use of an anti-tau ps422 antibody for the treatment of brain diseases

Publications (1)

Publication Number Publication Date
BRPI1012993A2 true BRPI1012993A2 (pt) 2018-01-16

Family

ID=42753372

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1012993A BRPI1012993A2 (pt) 2009-06-10 2010-06-08 "uso de um anticorpo anti-tau ps422 para o tratamento de doenças do cérebro"

Country Status (22)

Country Link
US (2) US8609097B2 (pt)
EP (1) EP2440578B1 (pt)
JP (2) JP2012529275A (pt)
KR (1) KR101429367B1 (pt)
CN (1) CN102459333B (pt)
AR (1) AR077016A1 (pt)
AU (1) AU2010257799B2 (pt)
BR (1) BRPI1012993A2 (pt)
CA (1) CA2762594C (pt)
CL (1) CL2011003122A1 (pt)
CO (1) CO6450613A2 (pt)
CR (1) CR20110606A (pt)
EC (1) ECSP11011514A (pt)
IL (1) IL216509A0 (pt)
MA (1) MA33339B1 (pt)
MX (1) MX2011012837A (pt)
NZ (1) NZ596187A (pt)
PE (1) PE20120543A1 (pt)
RU (1) RU2536247C2 (pt)
SG (1) SG176754A1 (pt)
TW (1) TW201103560A (pt)
WO (1) WO2010142423A2 (pt)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
RU2510400C9 (ru) 2007-09-26 2014-07-20 Чугаи Сейяку Кабусики Кайся Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
LT2975024T (lt) 2009-06-10 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Tetraciklininiai junginiai
EP3698788A1 (en) 2010-08-20 2020-08-26 Chugai Seiyaku Kabushiki Kaisha Composition comprising tetracyclic compound
SG189174A1 (en) 2010-10-11 2013-05-31 Biogen Idec Internat Neuroscience Gmbh Human anti-tau antibodies
SG10201509790YA (en) 2010-11-30 2015-12-30 Chugai Pharmaceutical Co Ltd Antigen-Binding Molecule Capable Of Binding To Plurality Of Antigen Molecules Repeatedly
GB201112056D0 (en) * 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
US9518101B2 (en) 2011-09-19 2016-12-13 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
MY178142A (en) * 2011-12-20 2020-10-05 Janssen Biotech Inc Anti-phf-tau antibodies and their uses
SG11201403365TA (en) * 2011-12-21 2014-07-30 Hoffmann La Roche Rapid method for cloning and expression of cognate antibody variable region gene segments
SG10201805410XA (en) 2012-05-31 2018-08-30 Univ Osaka City Therapeutic agent or prophylactic agent for dementia
NZ630542A (en) 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
TWI717591B (zh) 2012-08-24 2021-02-01 日商中外製藥股份有限公司 ＦｃγＲＩＩｂ特異性Ｆｃ區域變異體
JP5759568B2 (ja) 2012-09-25 2015-08-05 中外製薬株式会社 Ｒｅｔ阻害剤
KR102234324B1 (ko) * 2012-12-21 2021-03-31 바이오젠 엠에이 인코포레이티드 인간 항-타우 항체
WO2014096321A1 (en) * 2012-12-21 2014-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies specific to tau phosphorylated at serine 422 and uses for the treatment and diagnosis of tauopathies
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
TWI636062B (zh) 2013-04-02 2018-09-21 中外製藥股份有限公司 Fc region variant
PT3083680T (pt) * 2013-12-20 2020-03-17 Hoffmann La Roche Anticorpos humanizados anti-tau(ps422) e métodos de utilização
EP2899208A1 (en) * 2014-01-28 2015-07-29 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
EP3104870A4 (en) 2014-02-14 2017-09-13 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
BR112016021206B1 (pt) 2014-04-25 2022-07-12 Chugai Seiyaku Kabushiki Kaisha Composição farmacêutica, contendo composto tetracíclico em dose elevada e seu método de produção
RU2016146119A (ru) 2014-04-25 2018-05-29 Чугаи Сейяку Кабусики Кайся Новый кристалл тетрациклического соединения
AR100978A1 (es) * 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TW202136296A (zh) * 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
TWI765410B (zh) 2014-08-08 2022-05-21 日商中外製藥股份有限公司 ４環性化合物的非晶質體的用途
WO2016061389A2 (en) * 2014-10-16 2016-04-21 Genentech, Inc. Anti-alpha-synuclein antibodies and methods of use
RU2730668C2 (ru) * 2014-11-19 2020-08-24 Аксон Ньюросайенс Се Гуманизированные тау-антитела при болезни альцгеймера
KR102650420B1 (ko) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
WO2016114375A1 (ja) 2015-01-16 2016-07-21 中外製薬株式会社 併用医薬
CN112142844B (zh) 2015-02-05 2025-07-25 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
AR103713A1 (es) 2015-02-26 2017-05-31 Lilly Co Eli Anticuerpos contra tau y sus usos
JP6752222B2 (ja) 2015-04-16 2020-09-09 アルダー・バイオファーマシューティカルズ・インコーポレーテッド 羞明を処置、予防、または阻害するための抗ｐａｃａｐ抗体及びそれらの抗原結合性断片の使用
CA3258972A1 (en) 2015-06-05 2025-04-17 Ac Immune Sa TAU ANTIBODIES AND METHODS OF USING THEM
EP3744732B1 (en) * 2015-06-24 2025-09-10 F. Hoffmann-La Roche AG Humanized anti-tau(ps422) antibodies and methods of use
CN107849104B (zh) * 2015-07-06 2021-08-27 Ucb生物制药有限责任公司 Tau结合抗体
AU2016289753C1 (en) 2015-07-06 2021-08-05 UCB Biopharma SRL Tau-binding antibodies
JO3711B1 (ar) * 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
PT3334761T (pt) * 2015-08-13 2023-08-17 Univ New York Moléculas baseadas em anticorpo seletivo para o epítopo {p}ser404 da tau e os seus usos no diagnóstico e tratamento de tauopatias
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN109311977B (zh) 2016-04-15 2022-06-14 H.伦德贝克公司 人源化的抗pacap抗体及其用途
KR102551971B1 (ko) 2016-07-12 2023-07-07 하. 룬드벡 아크티에셀스카브 과인산화된 타우에 특이적인 항체 및 이의 사용 방법
MX2019001448A (es) 2016-08-05 2019-09-13 Chugai Pharmaceutical Co Ltd Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
US10988529B2 (en) 2016-08-09 2021-04-27 Eli Lilly And Company Combination therapy
CN117820467A (zh) 2016-12-07 2024-04-05 基因泰克公司 抗tau抗体和使用方法
UA128383C2 (uk) 2016-12-07 2024-07-03 Дженентек, Інк. Антитіло до тау-білка та спосіб його застосування
GB201700487D0 (en) 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic
JP2020508054A (ja) 2017-02-17 2020-03-19 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 抗タウ抗体及びその使用方法
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
TWI771389B (zh) 2017-03-16 2022-07-21 美商健生生物科技公司 抗phf-tau抗體及其用途
JOP20200074A1 (ar) 2017-10-16 2020-04-30 Eisai R&D Man Co Ltd أجسام مضادة ضد tau واستخداماتها
GB201720975D0 (en) * 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
KR20200116105A (ko) 2018-02-01 2020-10-08 얀센 백신스 앤드 프리벤션 비.브이. 타우에 특이적으로 결합하는 결합 분자
SG11202008579UA (en) 2018-03-05 2020-10-29 Janssen Pharmaceutica Nv Anti-phf-tau antibodies and uses thereof
KR20210024541A (ko) 2018-06-29 2021-03-05 추가이 세이야쿠 가부시키가이샤 난용성의 염기성 약제를 함유하는 의약 조성물
MY206038A (en) 2018-07-03 2024-11-26 Hoffmann La Roche Oligonucleotides for modulating tau expression
GB201811382D0 (en) 2018-07-11 2018-08-29 Taylor John Hermon Vaccine
JP2021530552A (ja) 2018-07-31 2021-11-11 イーライ リリー アンド カンパニー 併用療法
KR102635225B1 (ko) 2018-09-04 2024-02-07 추가이 세이야쿠 가부시키가이샤 4환성 화합물의 제조방법
GB2585252A (en) 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
BR112022026575A2 (pt) 2020-06-25 2023-01-17 Merck Sharp & Dohme Llc Anticorpos de alta afinidade que alvejam tau fosforilado em serina 413
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
TW202428602A (zh) 2022-09-15 2024-07-16 美商航海家醫療公司 Ｔａｕ結合化合物
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE386115T1 (de) 1991-12-06 2008-03-15 Max Planck Gesellschaft Verwendung von proteinkinasen zur diagnose und behandlung der alzheimer krankheit
WO1997034145A1 (fr) * 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
AU5508798A (en) 1996-11-19 1998-06-10 Trustees Of The University Of Pennsylvania, The Diagnostic and therapeutic reagents for alzheimer's disease
IT1312107B1 (it) * 1999-05-14 2002-04-04 Umberto Cornelli Glicosaminoglicani aventi peso molecolare medio di 2400 d atti altrattamento della demenza senile
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20070280935A1 (en) * 2006-04-07 2007-12-06 Bernd Bohrmann Antibody that recognizes phosphorylated peptides
EP1876185A1 (en) 2006-07-04 2008-01-09 F. Hoffmann-La Roche Ag An antibody which recognizes phosphorylated polypeptides

Also Published As

Publication number Publication date
US8609097B2 (en) 2013-12-17
RU2011152816A (ru) 2013-07-20
CA2762594C (en) 2017-02-28
KR101429367B1 (ko) 2014-08-11
SG176754A1 (en) 2012-01-30
RU2536247C2 (ru) 2014-12-20
JP6513617B2 (ja) 2019-05-15
HK1166331A1 (en) 2012-10-26
US20130310541A1 (en) 2013-11-21
CR20110606A (es) 2012-01-12
TW201103560A (en) 2011-02-01
AR077016A1 (es) 2011-07-27
CL2011003122A1 (es) 2012-07-20
CN102459333A (zh) 2012-05-16
WO2010142423A2 (en) 2010-12-16
US20110059093A1 (en) 2011-03-10
MA33339B1 (fr) 2012-06-01
PE20120543A1 (es) 2012-05-23
US9290567B2 (en) 2016-03-22
IL216509A0 (en) 2012-02-29
NZ596187A (en) 2013-11-29
EP2440578A2 (en) 2012-04-18
EP2440578B1 (en) 2017-03-08
MX2011012837A (es) 2011-12-16
JP2017031176A (ja) 2017-02-09
AU2010257799B2 (en) 2013-10-17
CN102459333B (zh) 2015-07-15
JP2012529275A (ja) 2012-11-22
AU2010257799A1 (en) 2011-12-01
ECSP11011514A (es) 2012-01-31
KR20120024952A (ko) 2012-03-14
CA2762594A1 (en) 2010-12-16
WO2010142423A3 (en) 2011-05-26
CO6450613A2 (es) 2012-05-31

Similar Documents

Publication Publication Date Title
BRPI1012993A2 (pt) "uso de um anticorpo anti-tau ps422 para o tratamento de doenças do cérebro"
BRPI0716844A2 (pt) Inidores de quinase úteis para o tratamento de doenças proliferativas
PT2426148E (pt) Anticorpo anti-rá-il-3 para se utilizar no tratamento de tumores do sangue
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
HUS1600048I1 (hu) Készítmény Fabry-kór kezelésére
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
BRPI0822625A2 (pt) "dispositivo espaçador modular para o tratamento de infecções por próteses"
BRPI0810082A2 (pt) 3-imidazolil-indóis para o tratamento de doenças proliferativas
BRPI0818799A2 (pt) Composições para o tratamento da doença de parkinson
PT2641596T (pt) Utilização de derivados de 1,3-difenilprop-2-en-1-ona para tratamento de doenças hepáticas
BR112014013843A2 (pt) uso de dispositivos para o tratamento de doenças neurológicas
BRPI0915084A2 (pt) composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, métodos para a profilaxia ou tratamento de um estado de doença ou uma condição e de câncer
HUE054495T2 (hu) Rák kezelésére szolgáló készítmény
BRPI0919920A2 (pt) compostos para tratamento de doenças e desordens oftálmicas
BRPI0817812A2 (pt) Uso de anticorpos trkb para o tratamento de distúrbios respiratórios
BRPI1006115A2 (pt) "agentes indutores de apoptose para o tratamento de câncer e doenças autoimunes".
BRPI1013698A2 (pt) métodos para tratamento com o uso de terapia de combinação
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
UY33094A (es) Procedimiento para la preparacion de dronedarona
IL209336B (en) Compositions for treating hyperproliferative diseases and uses thereof
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
CR9019A (es) Utilizacion de la agomelatina para la obtencion de medicamentos destinados al tratamiento del trastorno de ansiedad generalizada
BR112012004836A2 (pt) pirazinilpiridinas úteis para o tratamento de doenças proliferativas
PT2236149E (pt) Composição medicinal para o tratamento de doenças infeciosas respiratórias
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL